AUS
NZ
UK
CA
USA
IND
Inari Medical (NARI), a company specializing in minimally invasive solutions for venous and vascular diseases, released its second-quarter financial results on July 30. The company achieved notable revenue growth but also faced significant increases in operating expenses and a substantial net loss. For Q2, Inari Medical reported revenue of $145.8 million, representing a 22.5% increase from $119.0 million in the same quarter of 2023. However, despite this top-line growth, the company posted a net loss of $31.3 million, a sharp decline from the net income of $2.1 million reported in the prior-year period. These results aligned with management's earlier guidance.
Company Overview: Focus on Innovative Solutions
Inari Medical is known for its innovative, minimally invasive solutions designed to treat venous and other vascular diseases. The company is dedicated to developing products that address unmet and underserved medical conditions, with recent efforts focusing on expanding its venous thromboembolism product lines and advancing emerging therapies.
Quarterly Highlights: Revenue Growth and Increased Expenses
In Q2, Inari Medical saw strong performance in its venous thromboembolism segment, with revenues rising 20.7% year over year to $137.7 million. The emerging therapies segment also performed well, contributing $8.1 million, which represents a 65.6% increase. These results highlight the growing market adoption of Inari’s solutions.
The company’s gross profit increased to $125.8 million from $105.2 million a year earlier. However, its gross margin declined to 86.3% from 88.4%, a decrease attributed to changes in product mix, expenses related to ramping up new products, and costs associated with international expansion.
Operating expenses rose significantly, reflecting the company’s investment in growth. Personnel-related costs increased due to a larger headcount, and there were notable rises in professional fees and acquisition-related expenses. Specifically, research and development expenses climbed 18.1% to $24.9 million, while selling, general, and administrative expenses surged 33.5% to $114.2 million.
The company recorded a GAAP operating loss of $22.4 million, a significant increase from the $1.5 million loss reported in Q2 2023. The net loss of $31.3 million marked a sharp contrast to the net income of $2.1 million from the previous year.
Positive Developments and Financial Position
On a positive note, Inari Medical successfully launched VenaCore, a new device designed to treat deep vein thrombosis. Additionally, progress in the emerging therapies segment and favorable reimbursement updates for the LimFlow system contributed positively to the quarter’s results.
Despite the financial challenges, Inari Medical maintains a healthy cash position with $110 million in reserves, providing a solid foundation for ongoing operations and future growth.
